ALTANA PHARMA GROWTH OVERSEAS
Out of total group sales of 2.8 billion Deutschemarks ($1.67 million), Germany's Altana posted pharmaceutical sales, led by Byk Gulden, up 3% at 1.34 billion marks, and division profits of 126 million marks. Prescription medicine sales accounted for 62%.
Sales in Germany decreased by 7% to 640 million marks, largely as a result of the turmoil caused by health care reforms, while foreign turnover increased by 14% to 702 million marks. The latter improvement was mainly as a result of sales in Latin America, but also due to new product acquisitions in the USA and a new joint venture with Elmuquimica Farmaceutica in Spain.
Sales of Rx Drugs - Million Marks Therapy group 1992 1993 % Ch Cardiovascular 193 201 +4.1 Gastrointestinal 129 137 +6.2 Respiratory 133 135 +1.5 CNS 81 81 unch Rheumatism 50 50 unch Others 216 227 +5.1 Total 802 831 +3.6
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze